Last reviewed · How we verify
Placebo - UPA
This is a placebo control used in clinical trials and does not have an active pharmaceutical mechanism.
At a glance
| Generic name | Placebo - UPA |
|---|---|
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo-UPA appears to be a placebo formulation used as a control arm in Phase 3 clinical trials conducted by The University of Hong Kong. Without knowledge of the active comparator drug in these trials, the specific therapeutic mechanism cannot be determined. Placebos are inert substances used to establish efficacy and safety baselines in randomized controlled trials.
Approved indications
Common side effects
Key clinical trials
- Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (PHASE2)
- Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception (PHASE3)
- Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo (PHASE2)
- Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) (PHASE4)
- A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions (PHASE2)
- A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib (PHASE2)
- Dietary Seaweed and Early Breast Cancer: A Randomized Trial (NA)
- A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo - UPA CI brief — competitive landscape report
- Placebo - UPA updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI